变异株SARS-CoV-2 mRNA疫苗作为基础免疫或加强免疫系列在小鼠中引发广谱中和
研究在小鼠中评估了两种针对SARS-CoV-2变异株的mRNA疫苗:单价mRNA-1273.351编码B.1.351的刺突蛋白,mRNA-1273.211为mRNA-1273与mRNA-1273.351按1:1混合。两者均作为2剂基础免疫系列评估,mRNA-1273.351还作为既往接种mRNA-1273动物的加强剂量评估。结果显示mRNA-1273.351基础系列有效提高针对B.1.351的中和抗体滴度,mRNA-1273.211提供广谱跨变异株中和;第三剂(加强)mRNA-1273.351显著提高野生型和B.1.351特异性中和滴度。
要点
- mRNA-1273.351基础免疫系列有效提高小鼠针对B.1.351的中和抗体滴度。
- mRNA-1273.211基础免疫系列提供广谱跨变异株中和。
- 第三剂(加强)mRNA-1273.351显著提高野生型和B.1.351特异性中和滴度。
核心结论
- mRNA-1273.351基础系列有效提高针对B.1.351的中和抗体滴度,mRNA-1273.211提供广谱跨变异株中和。
- 第三剂(加强)mRNA-1273.351显著提高野生型和B.1.351特异性中和滴度。
研究设计与样本
- 在小鼠中初步评估两种更新mRNA疫苗:单价mRNA-1273.351编码B.1.351的刺突蛋白,mRNA-1273.211为mRNA-1273与mRNA-1273.351按1:1混合。
- 两种疫苗均作为2剂基础免疫系列在小鼠中评估;mRNA-1273.351还作为既往接种mRNA-1273动物的加强剂量评估。
主要发现
- mRNA-1273.351基础免疫系列有效提高针对B.1.351的中和抗体滴度。
- mRNA-1273.211基础免疫系列提供广谱跨变异株中和。
- 第三剂(加强)mRNA-1273.351显著提高野生型和B.1.351特异性中和滴度。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic. Safe and effective COVID-19 vaccines are now available, including mRNA-1273, which has shown 94% efficacy in prevention of symptomatic COVID-19 disease. However, the emergence of SARS-CoV-2 variants has led to concerns of viral escape from vaccine-induced immunity. Several variants have shown decreased susceptibility to neutralization by vaccine-induced immunity, most notably B.1.351 (Beta), although the overall impact on vaccine efficacy remains to be determined. Here, we present the initial evaluation in mice of 2 updated mRNA vaccines designed to target SARS-CoV-2 variants: (1) monovalent mRNA-1273.351 encodes for the spike protein found in B.1.351 and (2) mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351. Both vaccines were evaluated as a 2-dose primary series in mice; mRNA-1273.351 was also evaluated as a booster dose in animals previously vaccinated with mRNA-1273. The results demonstrated that a primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against B.1.351, while mRNA-1273.211 was effective at providing broad cross-variant neutralization. A third (booster) dose of mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers. Both mRNA-1273.351 and mRNA-1273.211 are being evaluated in pre-clinical challenge and clinical studies.
引用
- Wu K, Choi A, Koch M, et al. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Vaccine. 2021. PMID: 34815117. doi:10.1016/j.vaccine.2021.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。